

## Corrigendum to: Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe COVID-19 pneumonia - a single center experience

Marija Gomerčić Palčić<sup>\*1,2</sup>, Hana Matijaca<sup>3</sup>, Ivan Kruljac<sup>4</sup>, Lucija Vusić, Vedran Hostić<sup>5</sup>, Luka Vrbanić<sup>2</sup>, Fanika Mrsić<sup>6</sup>, Radovan Zrilić<sup>7</sup>, Ivana Čelap<sup>8</sup>, Petar Gaćina<sup>3,9</sup>

<sup>1</sup>School of Medicine, University of Zagreb, Zagreb, Croatia

<sup>2</sup>Department of Internal Medicine, Sestre milosrdnice University Hospital Center, Division of Pulmonology, Zagreb, Croatia

<sup>3</sup>Department of Internal Medicine, Sestre milosrdnice University Hospital Center, Division of Hematology, Zagreb, Croatia

<sup>4</sup>Solmed Group, Department: Poliklinika Solmed, Zagreb, Croatia

<sup>5</sup>Department of Anesthesiology, Intensive Care Medicine and Pain Management, Sestre milosrdnice University Hospital Center, Zagreb, Croatia

<sup>6</sup>Department of Internal Medicine, Sestre milosrdnice University Hospital Center, Division of Clinical Immunology and Rheumatology, Zagreb, Croatia

<sup>7</sup>Polyclinic for Respiratory Diseases, Dom zdravlja Zagreb - Zapad, Zagreb, Croatia

<sup>8</sup>Department of Clinical Chemistry, Sestre milosrdnice University Hospital Center, Croatia

<sup>9</sup>School of Dental Medicine, University of Zagreb, Zagreb, Croatia

\*Corresponding author: marijagomercic@yahoo.com

This is a correction of *Biochem Med (Zagreb)* 2023;33(2):020704. DOI: <https://doi.org/10.11613/BM.2023.020704>

Since the publication of the article, the authors have noticed that their first names and surnames in the by-line were listed in reverse. The correct by-line is presented above. We apologize to the authors for any inconvenience caused to the readers.